• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Catheters
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Injection Molding
    • Insert molding
    • Tools
  • Materials
    • Advanced Materials
    • Silicone
  • Research & Development
  • Suppliers

J&J wins FDA approval for ablation catheter

October 7, 2020 By Chris Newmarker

Biosense Webster Johnson & Johnson J&J  Thermocool SmartTouch SF ablation catheter
The Thermocool SmartTouch SF ablation catheter [Image courtesy of J&J’s Biosense Webster]

Johnson & Johnson (NYSE:JNJ) recently announced that its Biosense Webster business has secured FDA approval for its Thermocool SmartTouch SF ablation catheter.

The Thermocool SmartTouch received approval for the treatment of persistent atrial fibrillation, J&J announced yesterday.

The approval came after results from the 381-patient, prospective, multi-center Precept study that found that 80% of persistent AF patients experienced clinical success at 15 months after ablation therapy using the Thermocool SmartTouch SF catheter with Carto Visitag module.

The study also found people suffering from AF experienced a clinically meaningful improvement in their quality of life, with a significant reduction in healthcare resource utilization post-ablation.

“Every patient and every arrhythmia are unique,” said Dr. Francis Marchlinski, director of electrophysiology at the University of Pennsylvania Health System. “This approval and the Precept data provide evidence to support a tailored approach using the Carto 3 System and Thermocool SmartTouch SF Catheter to treat persistent AF patients, who are more at risk for stroke and other complications from their AF.”

Uri Yaron, worldwide president of Biosense Webster, added that persistent AF patients face a higher risk of complications such as stroke, heart failure, and death. “This approval and data from the Precept study help to further our commitment to advancing AF treatment, providing electrophysiologists with state-of-the-art options for their patients.”

Filed Under: Catheters Tagged With: Biosense Webster, Johnson & Johnson

Primary Sidebar

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Stay Current

Need Medical Tubing news in a minute?
We Deliver!

Medical Tubing + Extrusion newsletter get you caught up on all the mission critical news you need in medical tubing. Sign up today.

Enews Sign up
Tweets by MedTechDaily
Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

Medical Extrusion & Tubing

Subscribe
Advertise with us
About
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS